MX2019014572A - Métodos de ingeniería de carga superficial para la producción de anticuerpos biespecíficos. - Google Patents
Métodos de ingeniería de carga superficial para la producción de anticuerpos biespecíficos.Info
- Publication number
- MX2019014572A MX2019014572A MX2019014572A MX2019014572A MX2019014572A MX 2019014572 A MX2019014572 A MX 2019014572A MX 2019014572 A MX2019014572 A MX 2019014572A MX 2019014572 A MX2019014572 A MX 2019014572A MX 2019014572 A MX2019014572 A MX 2019014572A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- antibody
- bispecific antibody
- antibody production
- surface charge
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente descripción se relaciona con métodos para modificar el punto isoeléctrico de un anticuerpo; el método incluye proporcionar un anticuerpo que comprende un primer polipéptido que comprende una región variable de cadena pesada y un segundo polipéptido que comprende una región variable de cadena pesada, y sustituir en al menos uno del primer y el segundo polipéptidos del anticuerpo uno o más residuos de aminoácidos de la región variable de cadena pesada (VH) en las posiciones 7, 9, 11, 14, 41, 70, 74, 82a, 84 y 113, de acuerdo con el sistema de numeración de Kabat, en donde la sustitución aumenta o disminuye el punto isoeléctrico del anticuerpo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762515297P | 2017-06-05 | 2017-06-05 | |
PCT/IB2018/053996 WO2018224950A1 (en) | 2017-06-05 | 2018-06-04 | Methods of engineering surface charge for bispecific antibody production |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019014572A true MX2019014572A (es) | 2020-07-29 |
Family
ID=64566522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019014572A MX2019014572A (es) | 2017-06-05 | 2018-06-04 | Métodos de ingeniería de carga superficial para la producción de anticuerpos biespecíficos. |
Country Status (10)
Country | Link |
---|---|
US (2) | US11192951B2 (es) |
EP (1) | EP3634994A4 (es) |
JP (1) | JP7268011B2 (es) |
KR (2) | KR20240056666A (es) |
CN (1) | CN110959012A (es) |
AU (1) | AU2018279278A1 (es) |
BR (1) | BR112019025612A2 (es) |
CA (1) | CA3065447A1 (es) |
MX (1) | MX2019014572A (es) |
WO (1) | WO2018224950A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210126699A (ko) * | 2019-02-14 | 2021-10-20 | 메뤼스 엔.페. | 2개 이상의 항체를 포함하는 조성물의 제조 |
EP4126929A1 (en) * | 2020-03-25 | 2023-02-08 | Eli Lilly and Company | Multispecific binding proteins and methods of developing the same |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US7879328B2 (en) * | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
WO2006124269A2 (en) | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
AU2006299429B2 (en) | 2005-10-03 | 2012-02-23 | Xencor, Inc. | Fc variants with optimized Fc receptor binding properties |
EP4218801A3 (en) * | 2006-03-31 | 2023-08-23 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
PL2202245T3 (pl) | 2007-09-26 | 2017-02-28 | Chugai Seiyaku Kabushiki Kaisha | Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr |
JP2011530297A (ja) * | 2008-08-14 | 2011-12-22 | セファロン・オーストラリア・ピーティーワイ・リミテッド | バリアントドメイン抗体 |
WO2010131733A1 (ja) * | 2009-05-15 | 2010-11-18 | 中外製薬株式会社 | 抗axl抗体 |
GB201003701D0 (en) * | 2010-03-05 | 2010-04-21 | Cilian Ag | System for the expression of a protein |
SG10201800757TA (en) | 2010-04-20 | 2018-02-27 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
MX370848B (es) * | 2012-10-04 | 2020-01-08 | Dana Farber Cancer Inst Inc | Anticuerpos monoclonales humanos anti-pd-l1 y métodos de uso. |
TWI693073B (zh) * | 2012-12-21 | 2020-05-11 | 日商中外製藥股份有限公司 | 對gpc3標的治療劑療法為有效之患者投與的gpc3標的治療劑 |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
CA2904337A1 (en) * | 2013-03-14 | 2014-10-02 | Amgen Inc. | Chrdl-1 antigen binding proteins and methods of treatment |
CN107108729A (zh) * | 2015-02-05 | 2017-08-29 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il‑8‑结合抗体,及其应用 |
JP6725532B2 (ja) * | 2015-04-29 | 2020-07-22 | インスティテュート フォー リサーチ イン バイオメディシン | 多重特異性抗体によるサイトカインの非常に強力な中和およびその利用 |
CA2990518A1 (en) * | 2015-06-23 | 2016-12-29 | Innate Pharma | Multispecific nk engager proteins |
TW202342532A (zh) | 2015-09-18 | 2023-11-01 | 日商中外製藥股份有限公司 | Il-8結合抗體及其用途 |
JP6959912B2 (ja) * | 2015-09-23 | 2021-11-05 | ジェネンテック, インコーポレイテッド | 抗vegf抗体の最適化変異体 |
EP3405492B1 (en) * | 2016-01-21 | 2020-10-21 | Novartis AG | Multispecific molecules targeting cll-1 |
-
2018
- 2018-06-04 EP EP18813385.4A patent/EP3634994A4/en active Pending
- 2018-06-04 CA CA3065447A patent/CA3065447A1/en active Pending
- 2018-06-04 AU AU2018279278A patent/AU2018279278A1/en active Pending
- 2018-06-04 BR BR112019025612-1A patent/BR112019025612A2/pt unknown
- 2018-06-04 KR KR1020247013492A patent/KR20240056666A/ko not_active Application Discontinuation
- 2018-06-04 US US15/997,318 patent/US11192951B2/en active Active
- 2018-06-04 JP JP2020516972A patent/JP7268011B2/ja active Active
- 2018-06-04 KR KR1020197038976A patent/KR102661320B1/ko active IP Right Grant
- 2018-06-04 MX MX2019014572A patent/MX2019014572A/es unknown
- 2018-06-04 CN CN201880050468.8A patent/CN110959012A/zh active Pending
- 2018-06-04 WO PCT/IB2018/053996 patent/WO2018224950A1/en unknown
-
2021
- 2021-11-10 US US17/523,058 patent/US20220169741A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2020522573A (ja) | 2020-07-30 |
RU2019143638A3 (es) | 2022-02-10 |
EP3634994A1 (en) | 2020-04-15 |
US20220169741A1 (en) | 2022-06-02 |
EP3634994A4 (en) | 2021-06-30 |
CA3065447A1 (en) | 2018-12-13 |
US20190031764A1 (en) | 2019-01-31 |
JP7268011B2 (ja) | 2023-05-02 |
KR20200014385A (ko) | 2020-02-10 |
KR102661320B1 (ko) | 2024-05-03 |
AU2018279278A1 (en) | 2019-12-19 |
CN110959012A (zh) | 2020-04-03 |
US11192951B2 (en) | 2021-12-07 |
BR112019025612A2 (pt) | 2020-06-16 |
KR20240056666A (ko) | 2024-04-30 |
RU2019143638A (ru) | 2021-07-09 |
WO2018224950A1 (en) | 2018-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4249068A3 (en) | Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies | |
AU2018366199A1 (en) | Bispecific and monospecific antibodies using novel anti-PD-1 sequences | |
MX2019002946A (es) | Anticuerpos anti-pd-1 y sus usos. | |
MX2022012189A (es) | Composiciones que comprenden una variante del polipéptido cas12i2 y usos de las mismas. | |
SG11201806511XA (en) | Device and method for bonding substrates | |
SG10201807877TA (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
WO2018064307A3 (en) | Low-viscosity antigen binding proteins and methods of making them | |
MX2017004001A (es) | Humanizacion de anticuerpos a base de angulo de interdominio de cadena pesada-cadena ligera (vh-vl). | |
PH12017502213A1 (en) | Compositions and methods for treating celiac sprue disease | |
MX2019014572A (es) | Métodos de ingeniería de carga superficial para la producción de anticuerpos biespecíficos. | |
EA202190136A1 (ru) | Способ очистки антигена | |
MX2023014077A (es) | Composiciones de proteina anti-vegf y metodos para producir la misma. | |
EP3674313A4 (en) | NEW POLYPEPTIDE AND IMP PRODUCTION PROCESS USING IT | |
PH12016500403A1 (en) | An anti serum albumin fab-effector moiety fusion construct, and the preparing method thereof | |
WO2016089968A3 (en) | Thermoreversible hydrogels from the arrested phase separation of elastin-like polypeptides | |
MX2018014966A (es) | Peptidos monolipidados resistentes a proteasas. | |
SG11201908543WA (en) | Anti-pd-l1 antibody for detecting pd-l1 | |
MX2021016066A (es) | Anticuerpos heterodimericos que se unen a cd38 y cd3. | |
EP3741774A4 (en) | N-TERMINAL FUSION PARTNER FOR THE MANUFACTURING OF A RECOMBINANT POLYPEPTID AND PROCESS FOR THE MANUFACTURING OF A RECOMBINANT POLYPEPTID USING THESE | |
WO2019094669A3 (en) | Self-assembling protein structures and components thereof | |
WO2019130241A8 (es) | Mezcla de biocontroladores fúngicos para el control de hongos causales del brazo muerto de la vid | |
MX2019005552A (es) | Proteinas de union a antigenos biespecificas o biparatopicas y usos de las mismas. | |
WO2020127354A3 (en) | Polypeptides | |
WO2019103512A3 (ko) | 목적 단백질의 발현 효율을 증진시키기 위한 신규한 펩타이드 및 이를 포함하는 융합 단백질 | |
TW202430563A (zh) | 抗cd38抗體及其使用方法 |